Home > News > Advectus and Immune Announce Nano-Pharmaceutical Project Update
September 4th, 2003
Advectus and Immune Announce Nano-Pharmaceutical Project Update
Advectus Life Sciences Inc. announced today that it has acquired an option from Immune Network Ltd. which, if exercised, would give the Company an exclusive worldwide interest in a new nanotechnology-based formulation for the treatment of Alzheimer's disease based on compositions that penetrate the "blood-brain barrier" with existing drugs.
Nanobiotix strengthens its NanoXray pipeline with the launch of NBTX-TOPO development, the first nanotherapeutic with embedded radar: 1 product, 2 skills December 6th, 2013
The gene sequencing that everyone can afford in future December 6th, 2013
Dissolving electronics, energy: Kavli lectures at American Chemical Society meeting December 5th, 2013
Laser light at useful wavelengths from semiconductor nanowires: Nanowire lasers could work with silicon chips, optical fibers, even living cells December 5th, 2013